PFE vs PLX

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Protalix (PLX) maintains significant growth potential following the EU approval of Elfabrio's expanded dosing regimen and the triggered $25.0 million milestone, boosting projected cash to ~$50 million by April 2026. This, coupled with robust 2026 revenue guidance of $78–$83 million, strengthens its strategic market position in rare diseases. However, the FY 2025 TTM net loss of $6.6 million, a cle...